Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells

被引:39
作者
Jiang, Xiaofeng [1 ]
Zhu, Shimei [2 ]
Panetti, Tracee S. [1 ]
Bromberg, Michael E. [1 ]
机构
[1] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA
[2] Temple Univ, Sch Med, Dept Anat, Philadelphia, PA 19140 USA
关键词
tissue factor; factorVIIa; factor Xa; mammalian target of rapamycin; breast cancer;
D O I
10.1160/TH07-12-0722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with activated factor VII (FVIIa).TF is constitutively expressed in a variety of tumor cells and has been implicated in cellular signaling, angiogenesis, and tumor progression. Formation of TF-FVIIa complex and generation of downstream coagulation proteases, including activated factor X (FXa) and thrombin, initiate signaling by activation of protease-activated receptors (PARs).We have previously shown that TF-FVIIa-Xa complex formation promotes phosphorylation of p44/42 mitogen-activated protein kinase and Akt/protein kinase B in human breast cancer cells. In the present study, we show that formation of TF-FVIIa-FXa complex induces phosphorylation of mammalian target of rapamycin (mTOR) and p70 S6 kinase in a human breast cancer cell line, Adr-MCF-7. Activation of the mTOR pathway, which is probably mediated by PARI and/or PAR2, was associated with enhanced cell migration, a key step in the metastatic cascade. Inhibition of this pathway with the specific mTOR inhibitor, rapamycin, markedly decreased cell migration induced by formation of TF-FVIIa-FXa complex.These studies suggest that TF-FVIIa-mediated signaling modulates mTOR pathway activation, which regulates in part breast cancer cell migration. Targeting the TF-mediated cell signaling pathway might represent a novel strategy for the treatment of breast cancer.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 35 条
[1]   Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration [J].
Berven, LA ;
Willard, FS ;
Crouch, MF .
EXPERIMENTAL CELL RESEARCH, 2004, 296 (02) :183-195
[2]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[3]   Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa [J].
Camerer, E ;
Huang, W ;
Coughlin, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5255-5260
[4]   Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene [J].
Camerer, E ;
Rottingen, JA ;
Gjernes, E ;
Larsen, K ;
Skartlien, AH ;
Iversen, JG ;
Prydz, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32225-32233
[5]   Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].
Chan, S ;
Scheulen, ME ;
Johnston, S ;
Mross, K ;
Cardoso, F ;
Dittrich, C ;
Eiermann, W ;
Hess, D ;
Morant, R ;
Semiglazov, V ;
Borner, M ;
Salzberg, M ;
Ostapenko, V ;
Illiger, HJ ;
Behringer, D ;
Bardy-Bouxin, N ;
Boni, J ;
Kong, S ;
Cincotta, M ;
Moore, L .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322
[6]   Ribosomal S6 kinase signaling and the control of translation [J].
Dufner, A ;
Thomas, G .
EXPERIMENTAL CELL RESEARCH, 1999, 253 (01) :100-109
[7]   An expanding role for mTOR in cancer [J].
Guertin, DA ;
Sabatini, DM .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (08) :353-361
[8]   Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration [J].
Hjortoe, GM ;
Petersen, LC ;
Albrektsen, T ;
Sorensen, BB ;
Norby, PL ;
Mandal, SK ;
Pendurthi, UR ;
Rao, LVM .
BLOOD, 2004, 103 (08) :3029-3037
[9]   The mTOR pathway in breast cancer [J].
Hynes, Nancy E. ;
Boulay, Anne .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2006, 11 (01) :53-61
[10]   Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive [J].
Jacinto, E ;
Loewith, R ;
Schmidt, A ;
Lin, S ;
Rüegg, MA ;
Hall, A ;
Hall, MN .
NATURE CELL BIOLOGY, 2004, 6 (11) :1122-U30